MedTrace Logo

Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France

NCT04325646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2023-07-07

No results posted yet for this study

Summary

On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests.

Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.

This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.

As soon as it is available, serology will be performed on the collected samples.

Conditions

  • SARS (Severe Acute Respiratory Syndrome)
  • COVID-19

Interventions

OTHER

Human Biological samples

Blood samples for serological tests

OTHER

Human Biological samples

Blood samples, saliva, nasopharyngeal swab for serological tests

Sponsors & Collaborators

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Bruno HOEN, Pr · Institut Pasteur

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-13
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04325646 on ClinicalTrials.gov